1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JW LIFESCIENCE CORPORATION

JW LIFESCIENCE CORPORATION

KKRX:234080
10,520.00
KRW
+20.00
(+0.19%)
1,679.90EPS
6.78P/E
176.37BMarket Cap
Nov 16Next Earn
JW LIFESCIENCE CORPORATION
KRX:234080
(Korea Stock Exchange)

Recent

price

10,520.00

P/E

ratio

6.78

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
8,337.63
9,363.9
7,191.75
7,018.89
7,954.97
8,354.53
4,534.9
9,801.86
10,746.24
11,594.68
10,901.53
12,198.67
13,362.44
14,369.08
16,647.32
16,380.02
Revenue per Share
263.5
364.5
132.5
591
812.5
957.5
530
999
1,385
1,093
829
966
1,818
2,841
1,847
1,679.9
Basic EPS, GAAP
1,058.01
1,412.65
546
344.65
156.41
171.31
416.94
1,614.58
1,005
1,928.01
691.32
376.77
1,893.15
2,608.2
1,749.99
2,213.91
Free Cash Flow per Basic Share
- -
- -
- -
46.66
385.72
404.18
150.02
499.93
499.83
500.21
508.26
499.89
500.12
500.05
499.9
- -
Dividend per Share
3,380.45
3,673.48
4,391.75
4,859.06
5,231.08
5,702.83
6,447.98
6,899.94
7,743.54
8,367.39
8,491.82
9,062.74
10,293.69
12,944.82
14,245.04
14,644.44
Book Value per Share
3,224.06
3,434.17
4,097
4,530.98
4,961.27
5,430.65
6,176.94
6,503.27
7,368.96
8,003.58
8,148.8
8,769.82
10,027.24
7,924.66
9,267.72
9,704.3
Tangible Book Value per Share
10
10
12
16
16
16
32
16
16
16
16
15
15
15
15
15
Basic Weighted Avg Shares
84,121
89,091
88,614
111,121
125,950
132,290
143,600
155,230
170,221
183,521
169,817
188,931
206,860
222,478
257,829
253,706
Sales/Revenue/Turnover
11.41
9.83
8.94
13.15
14.81
16.35
16.56
15.17
17.48
21.5
16.73
14.34
14.92
16.12
12.89
13.14
Operating Margin (%)
11,212
11,191
11,535
12,006
12,620
13,172
11,122
11,098
11,626
12,246
13,245
14,956
15,531
15,737
18,193
18,479
Depreciation Expense
2,659
3,468
1,633
9,357
12,864
15,162
16,783
15,821
21,938
17,300
12,914
14,961
28,144
43,988
28,606
26,020
Net Income, GAAP
22.88
2.38
55.91
23.02
19.67
21.11
21.92
25.76
22.56
23.92
29.38
28.01
16.51
25.48
9.89
18.66
Effective Tax Rate (%)
3.16
3.89
1.84
8.42
10.21
11.46
11.69
10.19
12.89
9.43
7.6
7.92
13.61
19.77
11.09
10.26
Profit Margin (%)
-52,533
-46,149
-47,254
-40,502
-43,461
-33,889
-19,294
-15,201
-7,015
-12,772
-19,472
24,965
13,574
25,485
3,861
16,528
Working Capital
14,431
10,599
- -
2,620
8,414
14,035
15,429
10,430
5,467
1,573
1,642
30,047
215
33,075
1,339
1,486
LT Debt
63,718
68,358
69,541
76,941
82,832
90,302
102,101
109,257
122,615
132,494
131,492
140,332
159,393
200,445
220,578
226,763
Total Equity
- -
6.05
2.56
8.17
10.2
10.82
11.28
10.45
13.54
17.23
11.21
9.88
12.21
10.94
10.85
10.18
Return on Invested Capital (%)
- -
6.34
2.87
9.2
10.33
11.03
11.58
10.71
14.04
11.47
7.96
8.92
14.71
19.15
11.52
9.9
Return on Capital (%)
- -
6.21
2.56
12.78
16.1
17.51
17.45
14.97
18.92
13.56
9.78
11.01
18.78
24.45
13.59
11.92
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
49,233
40,705
30,880
LT Borrowings
- -
- -
- -
LT Finance Leases
1,339
1,546
1,486
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
198,977
194,486
176,369

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
88,289
87,988
82,003
Cash, Cash Equivalents & STI
10,489
12,202
12,079
Accounts Receivable, Net
43,233
42,226
40,433
Inventories
31,622
30,153
29,130
Total Current Liabilities
84,428
80,968
65,475
Payables & Accruals
- -
- -
- -
ST Debt
49,233
40,705
30,880
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.47%
11.07%
10.04%
Free Cash Flow
84.05%
59.33%
-32.88%
Net Income, GAAP
14.03%
19.99%
-34.97%
Sales/Revenue/Turnover
7.59%
7.34%
15.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
55,334
54,397
57,952
54,795
222,478
2025
68,631
62,261
62,610
64,328
257,829
2026
63,522
63,246
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
331
430
437
1,642.65
2,841
2025
394
722
314.24
416.72
1,847
2026
431.84
517
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
500.05
2025
- -
- -
- -
- -
499.9
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
JW Lifescience Corporation manufactures and supplies infusion solutions for intravenous administration in South Korea and internationally; its core products include basic intravenous fluids comprising water, electrolytes, and glucose; nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions such as antibiotics, total parenteral nutrition (TPN) products including Combiflex Lipid Central, Combiflex Lipid Peri, Combiflex MCT Peri, Freamine 10%, Hepatamine, and renal products; it also offers irrigation agents and dialysis solutions. Founded in 1994 and headquartered at 28 Hanjin 1-gil, Songak-eup, Dangjin-si, Chungcheongnam-do, South Korea, the company operates as an affiliate of JW Holdings Corporation and was formerly known as JW Co. Ltd. until its name change in April 2011. The company maintains world-class production facilities to support the domestic drug industry and public health, targeting hospitals and healthcare providers requiring parenteral nutrition and hydration therapies. No major acquisitions, partnerships, funding rounds, or strategic shifts for JW Lifescience Corporation appear in recent public records from 2024-2025, with operations focused on steady production and export of its established infusion portfolio.